➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,367,734

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,367,734 protect, and when does it expire?

Patent 8,367,734 protects PRIMATENE MIST and is included in one NDA.

Summary for Patent: 8,367,734
Title:Stable epinephrine suspension formulation with high inhalation delivery efficiency
Abstract: A stable suspension aerosol formulation of epinephrine is suitable for administration through inhalation comprising a therapeutically effective amount of epinephrine, hydrofluorocarbon propellant, co-solvent, surfactant, and antioxidant. The suspension aerosol formulation further comprises [pre-] pre-micronized epinephrine suspended in an alcohol/surfactant solution with hydrofluoroalkane propellant. The suspension formulation provides a highly efficient delivery of drug microparticles into the respirable region of patients' lungs and has the following advantages: lower dosage requirement, minimum alcohol content, with less impurities generated during storage, improved efficacy and safety, and exhibits no ozone depleting potential compared to a formulation containing chlorofluorocarbon.
Inventor(s): Gao; Jianxin (Norton, MA), Luo; James (Quincy, MA), Zhou; Rong (Fullerton, CA), Luo; Mary Ziping (Diamond Bar, CA), Zhang; Jack Yongfeng (Diamond Bar, CA)
Assignee: Amphastar Pharmaceuticals Inc. (Rancho Cucamonga, CA)
Application Number:12/776,338
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery; Dosage form;

Drugs Protected by US Patent 8,367,734

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Armstrong Pharms PRIMATENE MIST epinephrine AEROSOL, METERED;INHALATION 205920-001 Nov 7, 2018 OTC Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.